$AMRI (Albany Molecular Research Inc.)

$AMRI {{ '2016-07-11T14:35:05+0000' | timeago}} • Announcement

Contract research company $AMRI said that it has completed the earlier announced Prime European Therapeuticals SpA acquisition, a company that specializes in custom synthesis & making of active pharmaceutical ingredients. The transaction valued at EUR 315MM was financed by $AMRI through the issuance of common stock, seller notes & the rest in cash.

$ISRG {{ '2017-10-23T16:52:19+0000' | timeago}} • Webcast

$ISRG upped its FY17 procedure growth guidance range to 15% to 16% from prior estimate of 14% to 15% above the 753,000 procedures performed in 2016. In regards to system placements, although the proportion of 3Q17 systems placed under operating leases was slightly lower than 2Q17, the company continues to expect an upward trend for FY17.

$ISRG {{ '2017-10-23T16:49:27+0000' | timeago}} • Webcast

$ISRG continues to launch its da Vinci X systems in new regions, as it launched in nine countries during 3Q17 and anticipates adding four more in 4Q17. The company said that da Vinci Xi makes up roughly 75% of new placements, da Vinci X makes up approx. 10% of new placements in its limited early launch and with the balance made up by Si technology.

$CBM {{ '2017-10-23T16:20:28+0000' | timeago}} • Announcement

$CBM has completed the expansion to its large scale production capacity at its Charles City, Iowa plant. The investment included the installation of 1,000 and 4,000 gallon glass lined reactors in addition to ancillary equipment. This brings the total capacity at the Charles City facility to approx. 107,000 gallons.

$UTHR {{ '2017-10-23T15:44:25+0000' | timeago}} • Announcement

$UTHR announced approval by the US FDA of a new inhalation device, called the TD-300/A, for use with Tyvaso (treprostinil) Inhalation Solution. Tyvaso was originally approved by the FDA for the treatment of pulmonary arterial hypertension.

$ENTA {{ '2017-10-23T15:37:49+0000' | timeago}} • Announcement

$ENTA announced positive results in terms of safety and tolerability from its Phase 1 clinical study of EDP-305, its lead FXR agonist for non-alcoholic steatohepatitis and primary biliary cholangitis.

$BABY {{ '2017-10-23T14:50:44+0000' | timeago}} • Announcement

$BABY announced that it will be Aspect Imaging, Ltd.’s exclusive selling agent for the Embrace Neonatal MRI system in the US. The Embrace Neonatal MRI System is designed specifically for imaging of the neonatal head. $BABY will also gain equity participation in Aspect Imaging, Ltd.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

$ISRG {{ '2017-10-19T20:24:48+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical Earnings AlphaGraphic: Q3 2017 Highlights

$DEPO {{ '2017-10-18T15:44:41+0000' | timeago}} • Announcement

$DEPO appointed Santosh Vetticaden as SVP, Chief Medical and Scientific Officer. Most recently, he held the position of Interim CEO of Insys Therapeutics Inc. Vetticaden currently serves on the board of Heluna Health (formerly Public Health Foundation Enterprises).

$HAE {{ '2017-10-18T15:38:09+0000' | timeago}} • Announcement

$HAE elected Robert Abernathy to its BoD. Abernathy has led major medical businesses in North America and Europe with Halyard Health, Inc. Abernathy served as Chairman of the Board and CEO of Halyard Health Inc., a $KMB spinoff medical technology company specializing in important patient health care needs.

$HAE {{ '2017-10-18T15:03:18+0000' | timeago}} • Announcement

$HAE elected Robert Abernathy to its BoD. Abernathy previously served on the Board of The Advanced Medical Technology Association (AdvaMed).

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$AMGN {{ '2017-10-17T14:34:06+0000' | timeago}} • Announcement

$AMGN has entered into a neuroscience research collaboration with Boston Children's Hospital, which aims at identifying novel pain targets based on human genetic analyses. The one-year collaboration will focus on patients with genetic anomalies of pain sensitivity.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$MDT {{ '2017-10-16T20:09:05+0000' | timeago}} • Announcement

$MDT said its Medtronic Care Management Services (MCMS) business and American Well entered into a strategic partnership. Under the agreement, the businesses will work together to enable patient access to American Well's telemedicine services on MCMS' video-enabled platforms, and to allow bi-directional data flow between the two parties.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$DEPO {{ '2017-10-10T13:44:58+0000' | timeago}} • Announcement

$DEPO said that as a result of the disruption to manufacturing operations in Puerto Rico due to Hurricane Maria, it is experiencing temporary delays in packaging and delivery of certain dosage strengths of NUCYNTA ER at the facility in Puerto Rico. Consequently, $DEPO expects its 4Q17 product revenue to be negatively impacted by less than $10MM.

$Q {{ '2017-10-10T12:37:04+0000' | timeago}} • Announcement

$Q announced the pricing of the offering of €420MM in gross proceeds of senior notes to be issued by its subsidiary, Quintiles IMS Incorporated. The notes will bear interest at a rate of 2.875% and will pay interest semi-annually in arrears on March 15 and Sept 15 of each year, beginning on March 15, 2018. The notes will mature on Sept 15, 2025.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
ACET (Aceto Corp.)
Friday, August 25 2017 - 1:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
XON (Intrexon Corporation)
Wednesday, August 9 2017 - 9:30pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
CRL (Charles River Laboratories International, Inc.)
Wednesday, August 9 2017 - 12:30pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
DEPO (DepoMed Inc.)
Monday, August 7 2017 - 8:30pm
ENTA (Enanta Pharmaceuticals, Inc.)
Monday, August 7 2017 - 8:30pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
CBM (Cambrex Corporation.)
Friday, August 4 2017 - 12:30pm
Q (Quintiles Transnational Holdings Inc.)
Thursday, August 3 2017 - 1:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
EXEL (Exelixis, Inc.)
Wednesday, August 2 2017 - 9:00pm
OSUR (OraSure Technologies, Inc.)
Wednesday, August 2 2017 - 9:00pm
CAH (Cardinal Health, Inc.)
Wednesday, August 2 2017 - 12:30pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
SNMX (Senomyx Inc.)
Thursday, July 27 2017 - 9:00pm
UTHR (United Therapeutics Corporation)
Thursday, July 27 2017 - 1:00pm
ICLR (ICON Public Limited Company)
Thursday, July 27 2017 - 1:00pm

AlphaGraphics you may like